Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Researchers from the Universities of Cambridge, Bristol, and Edinburgh have revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes.
劍橋大學、布里斯托大學和愛丁堡大學的研究人員透露，COVID-19疫苗可能會顯著降低動脈血栓的發病率，這是心臟病發作和中風的主要原因。
The study, published in Nature Communications and supported by the British Heart Foundation Data Science Centre at Health Data Research U.K., analyzed de-identified health records of 46 million adults provided by NHS England.
這項研究發表於《自然·通訊》雜誌上，並得到了英國心臟基金會數據科學中心和英國衛生數據研究機構提供的4600萬成年人的匿名健康記錄的支持。
Using health records from 45.7 million adults in England between December 2020 and January 2022, the study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second, and booster doses of brands and combinations of COVID-19 vaccines used during the U.K. vaccination program with the incidence before or without the corresponding vaccination.
利用英國2020年12月至2022年1月期間的4570萬成年人健康記錄，該研究比較了英國疫苗接種計劃中使用的COVID-19疫苗品牌和組合的第一劑、第二劑和加強劑疫苗接種前或未接種時以及接種後至第26周的血栓和心血管併發症發病率。
The incidence of common arterial thrombotic events (mainly acute myocardial infarction or heart attack and ischaemic stroke) was generally lower after each vaccine dose, brand, and combination.
每種疫苗劑量、品牌和組合接種後，通常常見的動脈血栓事件（主要爲急性心肌梗死或心臟病發作和缺血性卒中）發病率都較低。
There was a higher incidence of previously reported rare harms after vaccination, including:
接種後還出現了包括以下已經報道的罕見不良反應：
- Vaccine-induced thrombotic thrombocytopenia after the first AstraZeneca Plc's (NASDAQ:AZN) vaccine (ChAdOx1).
- Myocarditis and pericarditis (inflammation of the heart muscle and outer lining) after the first, second, and transiently after booster mRNA vaccination, including BioNTech SE (NASDAQ:BNTX) / Pfizer Inc (NYSE:PFE) BNT-162b2 and Moderna Inc's (NASDAQ:MRNA) vaccine, mRNA-1273.
- 在接種了阿斯利康股份有限公司（NASDAQ:AZN）的第一劑疫苗（ChAdOx1）後出現了疫苗相關性血栓性血小板減少症。
- 在接種mRNA疫苗，包括BioNTech SE (NASDAQ:BNTX) / 輝瑞公司（NYSE:PFE）的BNt-162b2和Moderna Inc（NASDAQ:MRNA）的mRNA-1273的第一、第二劑以及短暫的強化劑後，出現了心肌炎和心包炎（心臟肌肉和外層襯的炎症）。
For all vaccine brands and doses, adjusted hazard ratios (aHRs) were lower in the first few weeks than in later weeks. The aHR profiles for acute myocardial infarction and ischaemic stroke were similar to those of composite arterial thrombosis for all vaccine brands and doses.
對於所有疫苗品牌和劑量，調整過的風險比（aHRs）在最初幾周比以後的幾周要低。對於所有疫苗品牌和劑量，急性心肌梗死和缺血性卒中的aHR曲線與所有動脈血栓的組合相似。
Similarly, the incidence of common venous thrombotic events (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination.
同樣，接種後常見的靜脈血栓事件（主要爲肺栓塞和下肢深靜脈血栓）的發病率較低。
These findings support the wide uptake of future COVID-19 vaccination programs.
這些發現支持未來COVID-19疫苗接種計劃的廣泛推廣。
In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines."
今年7月，阿斯利康因「更新的疫苗過多」而宣佈了其COVID-19疫苗Vaxzevria的全球停產。
Earlier, Pfizer raised its 2024 guidance to $8.5 billion from $8 billion but reaffirmed that $5 billion would come from BioNTech's partnered Comirnaty-COVID-19 vaccine.
此前，輝瑞將其2024年的業績預期從800億美元提高至850億美元，但重申500億美元將來自BioNTech合作推出的Comirnaty-COVID-19疫苗。
Moderna also lowered its 2024 sales guidance on Thursday due to weaker demand for its COVID-19 vaccines.
Moderna也因其COVID-19疫苗的需求疲軟而在週四下調了2024年的銷售業績指引。
- General Motors Plans Major Overhaul And Job Cuts In China: Report.
- 通用汽車計劃在中國進行大規模改組和裁員：報告。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。